Get started
Author

Susanne H.C. Baumeister

Observed names: Susanne Baumeister, Susanne H Baumeister, Susanne H C Baumeister, Susanne H. Baumeister, Susanne H. C. Baumeister
ORCID: 0000-0003-3846-5156
Observed ORCID: 0000-0003-3846-5156
OpenAlex ID: A5066615406
Coinhibitory Pathways in Immunotherapy for Cancer
2016 · Susanne H. Baumeister, Gordon J. Freeman, et al. · Annual Review of Immunology · 912
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2018 · Susanne H. Baumeister, Joana Murad, et al. · Cancer Immunology Research · 331
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
2022 · Liora M. Schultz, Anne Eaton, et al. · Journal of Clinical Oncology · 73
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
2020 · Lina Driouk, Joanina K. Gicobi, et al. · Frontiers in Immunology · 72
PDF
CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial
2023 · Nirali N. Shah, Sarah K. Tasian, et al. · Blood · 69
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice
2016 · Marie-Louise Sentman, Joana M Murad, et al. · The Journal of Immunology · 61
Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
2020 · Susanne H. C. Baumeister, Benedetta Rambaldi, et al. · Frontiers in Immunology · 55
PDF
Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
2018 · Joana M. Murad, Susanne H. Baumeister, et al. · Cytotherapy · 53
Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
2016 · Sarah Nikiforow, Lillian Werner, et al. · Blood · 40
Immunodomination in the Evolution of Dominant Epitope-Specific CD8+ T Lymphocyte Responses in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
2006 · Michael H Newberg, Kimberly J McEvers, et al. · The Journal of Immunology · 37
PDF
Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis (carHLH) Predicts Poor Survival with Real-World Use of Tisagenlecleucel for B-ALL
2022 · Kevin O. McNerney, Stephanie J. Si Lim, et al. · Blood Advances · 35
PDF
Increased Loss of CCR5 + CD45RA − CD4 + T Cells in CD8 + Lymphocyte-Depleted Simian Immunodeficiency Virus-Infected Rhesus Monkeys
2008 · Ronald S. Veazey, Paula M. Acierno, et al. · Journal of Virology · 34
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.
2016 · Sarah Nikiforow, Joana Murad, et al. · Journal of Clinical Oncology · 30
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry
2025 · Samuel John, Kevin J. Curran, et al. · Blood Advances · 25
PDF
B-cell–directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates
2024 · James Kaminski, Ryan A. Fleming, et al. · Blood · 25
PDF
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
2023 · Holly Wobma, Malika Kapadia, et al. · Blood Advances · 24
PDF
Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation
2022 · Susanne H. C. Baumeister, Gopi S. Mohan, et al. · Frontiers in Oncology · 23
PDF
Contribution of CD8+T Cells to Containment of Viral Replication and Emergence of Mutations inMamu-A*01-Restricted Epitopes in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
2008 · Eun-Young Kim, Ronald S. Veazey, et al. · Journal of Virology · 23
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
2025 · Hannah Lust, Liora M. Schultz, et al. · Blood Advances · 18
G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity
2007 · Susanne H. C. Baumeister, Kristina Hölig, et al. · Blood · 18
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
2023 · Valentin Barsan, Yimei Li, et al. · EClinicalMedicine · 15
PDF
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
2019 · Lina Driouk, Joanina Gicobi, et al. · Blood · 12
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML
2025 · Swati Naik, Richard Aplenc, et al. · Blood Advances · 9
PDF
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.
2024 · Rayne H. Rouce, Susanne H.C. Baumeister, et al. · Journal of Clinical Oncology · 5
PDF
Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy
2024 · Hannah Lust, Gregory Roloff, et al. · Transplantation and Cellular Therapy · 4
Works count: 71
Citation count: 2,029
H-index: 18
I10-index: 22
Year
Topic
Type